Galmed Pharmaceuticals Ltd. rebranded as Eocene Ltd., changing its Nasdaq ticker symbol from GLMD to EOCN effective September 10, 2026, to reflect a strategic pivot toward gastrointestinal innovation following the acquisition of Colospan Ltd. The company also terminated its Standby Equity Purchase Agreement with Yorkville, having raised approximately $7.3 million through the issuance of 437,947 ordinary shares prior to termination. Shareholders approved amendments to the Articles of Association at an Annual General Meeting on September 3, 2026. Eocene Ltd. is a gastrointestinal-focused medtech and biopharmaceutical company developing therapeutic and device solutions for GI diseases and cancers.

Galmed Pharmaceuticals Ltd. filed its unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2026. The company reported a net loss of $4,633 thousand for the first half of 2026, an increase from $3,599 thousand in the prior year period. Operating expenses rose to $4,819 thousand, driven by higher research and development costs of $3,142 thousand compared to $1,692 thousand previously. The company acquired Colospan Ltd., resulting in $4,642 thousand in other intangible assets and $1,764 thousand in goodwill on the balance sheet as of June 30, 2026. Cash and cash equivalents decreased to $2,885 thousand from $3,985 thousand at year-end 2025. Galmed Pharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of treatments for gastrointestinal disorders.